Drug-induced liver injury: the dawn of biomarkers?

by Weiler, Stefan, Merz, Michael, Kullak-Ublick, Gerd A.
Published 2015

The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future

by Watkins, Paul B., Merz, Michael, Avigan, Mark I., Kaplowitz, Neil, Regev, Arie, Senior, John R.
Published 2014

Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)

by Kullak-Ublick, Gerd A., Merz, Michael, Griffel, Louis, Kaplowitz, Neil, Watkins, Paul B.
Published 2014

Methodology to Assess Clinical Liver Safety Data

by Merz, Michael, Lee, Kwan R., Kullak-Ublick, Gerd A., Brueckner, Andreas, Watkins, Paul B.
Published 2014

A Novel Glutamyl (Aspartyl)-Specific Aminopeptidase A from Lactobacillus delbrueckii with Promising Properties for Application

by Stressler, Timo, Ewert, Jacob, Merz, Michael, Funk, Joshua, Claaßen, Wolfgang, Lutz-Wahl, Sabine, Schmidt, Herbert, Kuhn, Andreas, Fischer, Lutz
Published 2016

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development

by Regev, Arie, Seeff, Leonard B., Merz, Michael, Ormarsdottir, Sif, Aithal, Guruprasad P., Gallivan, Jim, Watkins, Paul B.
Published 2014

Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials

by Avigan, Mark I., Bjornsson, Einar S., Pasanen, Markku, Cooper, Charles, Andrade, Raul J., Watkins, Paul B., Lewis, James H., Merz, Michael
Published 2014